1. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
2. Prognostic validation of SKY92 and its combination with ISS in an independent cohort of patients with multiple myeloma;Beers E.H.;Clin. Lymphoma Myeloma Leuk.,2017
3. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma;Bergsagel P.L.;Blood,2005
4. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high‐risk abnormalities in newly diagnosed multiple myeloma;Binder M.;Blood Cancer J.,2017
5. No survival improvement in patients with high‐risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades;Chalopin T.;Br. J. Haematol.,2021